Top

Published in:

01-06-2022 | SCLC | Review Article

Paraneoplastic neurological syndrome: growing spectrum and relevance

Authors: Valakunja Harikrishna Ganaraja, Mohamed Rezk, Divyanshu Dubey

Published in: Neurological Sciences | Issue 6/2022

Abstract

Paraneoplastic neurological syndromes (PNSs) are group of disorders affecting one or multiple parts of the neuroaxis associated with underlying tumors. An antibody or autoantigen-specific cell-mediated immune response against neural antigen expressed in the tumor is the potential etiology for these rare but refractory disorders. In recent years, wide variety of neurological presentations and autoantibodies has been associated with paraneoplastic autoimmunity, leading to formulation of an updated expert consensus PNS diagnostic criteria. Recognition of these phenotypes and use of serological biomarkers may aid neurologists in early diagnosis of PNS cases encountered in the inpatient or outpatient practice. In this review article, we provide an overview of various clinical, radiological, and immunopathological characteristics of PNS. Furthermore, we discuss the updated PNS criteria and increasing recognition of neurological presentations resembling the PNS among patients receiving immune checkpoint inhibitors.

Giometto B, Grisold W, Vitaliani R et al (2010) Paraneoplastic neurologic syndrome in the PNS euronetwork database: a European study from 20 centers. Arch Neurol 67:330–5. https://doi.org/10.1001/archneurol.2009.341CrossRefPubMed

Schulz P, Prüss H (2015) Hirnsymptome bei Carcinomatose "-Hermann Oppenheim and an early description of a paraneoplastic neurological syndrome. J Hist Neurosci 24:371–7. https://doi.org/10.1080/0964704X.2015.1021120CrossRefPubMedPubMedCentral

Wilkinson PC, Zeromski J (1965) Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain 88:529–83. https://doi.org/10.1093/brain/88.3.529CrossRefPubMed

Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–54. https://doi.org/10.1056/nejmra023009CrossRefPubMed

Vogrig A, Gigli GL, Segatti S et al (2019) (2019) Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2671(267):26–35. https://doi.org/10.1007/S00415-019-09544-1CrossRef

Hébert J, Riche B, Vogrig A et al (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol neuroinflammation 7:e883. https://doi.org/10.1212/NXI.0000000000000883CrossRef

Shah S, Flanagan EP, Paul P et al (2022) Population-based epidemiology study of paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammation 9:e1124. https://doi.org/10.1212/NXI.0000000000001124CrossRef

Joseph CG, Darrah E, Shah AA, et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (80- ) 343:. https://doi.org/10.1126/science.1246886

Villadangos JA (2007 Jul) Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7(7):543–555. https://doi.org/10.1038/nri2103CrossRefPubMed

10.

Darnell RB (1996) Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. U. S. A. May 14;93(10):4529–36. https://doi.org/10.1073/pnas.93.10.4529.

11.

Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell. Nature 393:474–8. https://doi.org/10.1038/30989CrossRefPubMed

12.

Zekeridou A, Lennon VA (2019) Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc 94(9):1865–1878. https://doi.org/10.1016/j.mayocp.2019.02.003CrossRefPubMed

13.

Graus F, Vogrig A, Muñiz-Castrillo S, et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol - Neuroimmunol Neuroinflammation 8. https://doi.org/10.1212/NXI.0000000000001014

14.

Henson RA, Hoffman HL, Urich H (1965) Encephalomyelitis with carcinoma. Brain 88:449–464. https://doi.org/10.1093/BRAIN/88.3.449CrossRefPubMed

15.

Graus F, Keime-Guibert F, Reñe R, et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. 124(Pt 6):1138–48. https://doi.org/10.1093/brain/124.6.1138.

16.

Graus F, Keime-Guibert F, Reñe R et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124:1138–1148. https://doi.org/10.1093/BRAIN/124.6.1138CrossRefPubMed

17.

Yu Z, Kryzer TJ, Griesmann GE et al (2001) CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49:146–54. https://doi.org/10.1002/1531-8249(20010201)49:2%3c146::AID-ANA34%3e3.0.CO;2-ECrossRefPubMed

18.

Dubey D, Lennon VA, Gadoth A et al (2018) Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology 90:e103–e110. https://doi.org/10.1212/WNL.0000000000004803CrossRefPubMed

19.

Gultekin SH, Rosenfeld MR, Voltz R et al (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123:1481–94. https://doi.org/10.1093/brain/123.7.1481CrossRefPubMed

20.

Dalmau J, Graus F, Villarejo A et al (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831–44. https://doi.org/10.1093/brain/awh203CrossRefPubMed

21.

Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration: I.A clinical analysis of 55 anti–Yo antibody–positive patients. Neurology 42:. https://doi.org/10.1212/wnl.42.10.1931

22.

Dubey D, Kryzer T, Guo Y et al (2021) Leucine Zipper 4 autoantibody: a novel germ cell tumor and paraneoplastic biomarker. Ann Neurol 89:1001–1010. https://doi.org/10.1002/ANA.26050CrossRefPubMed

23.

Vogrig A, Péricart S, Pinto A-L et al (2021) Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Commun 3:fcab185. https://doi.org/10.1093/braincomms/fcab185CrossRefPubMedPubMedCentral

24.

De Graaff E, Maat P, Hulsenboom E et al (2012) Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 71:815–24. https://doi.org/10.1002/ana.23550CrossRefPubMed

25.

Ruiz-García R, Martínez-Hernández E, Joubert B et al (2020) Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol - Neuroimmunol Neuroinflammation 7:658. https://doi.org/10.1212/NXI.0000000000000658CrossRef

26.

Valencia-Sanchez C, Knight AM, Hammami MB et al (2022) Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. J Neurol Neurosurg Psychiatry 93:196–200. https://doi.org/10.1136/JNNP-2021-326656CrossRefPubMed

27.

Do LD, Gupton SL, Tanji K et al (2019) TRIM9 and TRIM67 are new targets in paraneoplastic cerebellar degeneration HHS Public Access. Cerebellum 18:245–254. https://doi.org/10.1007/s12311-018-0987-5CrossRefPubMedPubMedCentral

28.

Gorman MP (2010) Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus- ataxia syndrome. Curr Opin Pediatr 22(6):745–750. https://doi.org/10.1097/MOP.0b013e32833fde3fCrossRefPubMed

29.

Bataller L, Graus F, Saiz A, Vilchez JJ (2001) Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124:437–43. https://doi.org/10.1093/brain/124.2.437CrossRefPubMed

30.

Pranzatelli MR, Tate ED, McGee NR (2017) Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol 8:468. https://doi.org/10.3389/fneur.2017.00468CrossRefPubMedPubMedCentral

31.

Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann Neurol 53:580–7. https://doi.org/10.1002/ana.10518CrossRefPubMed

32.

Oh SY, Kim JS, Dieterich M (2019) Update on opsoclonus–myoclonus syndrome in adults. J Neurol 266(6):1541–1548. https://doi.org/10.1007/s00415-018-9138-7CrossRefPubMed

33.

Camdessanché JP, Antoine JC, Honnorat J, et al (2002) Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 125:. https://doi.org/10.1093/brain/awf006

34.

Molinuevo JL, Graus F, Serrano C et al (1998) Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 44:976–80. https://doi.org/10.1002/ana.410440620CrossRefPubMed

35.

Antoine JC, Camdessanché JP (2017) Paraneoplastic neuropathies. Curr Opin Neurol 30:513–520. https://doi.org/10.1097/WCO.0000000000000475CrossRefPubMed

36.

Dubey D, Jitprapaikulsan J, Bi H et al (2019) Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology 93:e1873–e1880. https://doi.org/10.1212/WNL.0000000000008472CrossRefPubMed

37.

Lee H-R, Lennon VA, Camilleri M, Prather CM (2001) Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 96:373–9. https://doi.org/10.1111/j.1572-0241.2001.03454.xCrossRefPubMed

38.

Koike H, Sobue G (2013) Paraneoplastic neuropathy. Handb Clin Neurol 115:713–726. https://doi.org/10.1016/B978-0-444-52902-2.00041-2CrossRefPubMed

39.

O’neill JH, Murray NMF, Newsom-davis J (1988) The lambert-eaton myasthenic syndrome: A REVIEW of 50 cases. Brain 111:577–96. https://doi.org/10.1093/brain/111.3.577CrossRefPubMed

40.

Schoser B, Eymard B, Datt J, Mantegazza R (2017) Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 264(9):1854–1863. https://doi.org/10.1007/s00415-017-8541-9CrossRefPubMed

41.

Motomura M, Lang B, Johnston I et al (1997) Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147:35–42. https://doi.org/10.1016/S0022-510X(96)05303-8CrossRefPubMed

42.

Pittock SJ, Parisi JE, McKeon A et al (2010) Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 67:1109–15. https://doi.org/10.1001/archneurol.2010.209CrossRefPubMed

43.

Mandel-Brehm C, Dubey D, Kryzer TJ, et al (2019) Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 381. https://doi.org/10.1056/nejmoa1816721

44.

Dubey D, Wilson MR, Clarkson B et al (2020) Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic kelch-like protein-11 encephalitis. JAMA Neurol 77:1420–1429. https://doi.org/10.1001/jamaneurol.2020.2231CrossRefPubMed

45.

Torres-Vega E, Mancheño N, Cebrián-Silla A et al (2017) Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology 88:1235–1242. https://doi.org/10.1212/WNL.0000000000003778CrossRefPubMedPubMedCentral

46.

Irani SR, Pettingill P, Kleopa KA et al (2012) Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 72:241–55. https://doi.org/10.1002/ana.23577CrossRefPubMed

47.

Forsyth PA, Dalmau J, Graus F et al (1997) Motor neuron syndromes in cancer patients. Ann Neurol 41:722–30. https://doi.org/10.1002/ana.410410608CrossRefPubMed

48.

Vogrig A, Joubert B, Maureille A et al (2019) Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol 266:398–410. https://doi.org/10.1007/s00415-018-9143-xCrossRefPubMed

49.

Dericioglu N, Gocmen R, Tan E (2018) Paraneoplastic striatal encephalitis and myelitis associated with anti-CV2/CRMP-5 antibodies in a patient with small cell lung cancer. Clin Neurol Neurosurg 170:117–119. https://doi.org/10.1016/j.clineuro.2018.05.010CrossRefPubMed

50.

Liu Z, Jiao L, Qiu Z et al (2019) Clinical characteristics of patients with paraneoplastic myelopathy. J Neuroimmunol 330:136–142. https://doi.org/10.1016/j.jneuroim.2019.03.001CrossRefPubMed

51.

Li K, Zhan Y, Shen X (2020) Multiple intracranial lesions with lung adenocarcinoma: a rare case of MOG-IgG-associated encephalomyelitis. Mult Scler Relat Disord 42:102064. https://doi.org/10.1016/j.msard.2020.102064CrossRefPubMed

52.

Blum P, Jankovic J (1991) Stiff‐person syndrome: an autoimmune disease. Mov Disord 6. https://doi.org/10.1002/mds.870060104

53.

Sarva H, Deik A, Ullah A, Severt WL (2016) Clinical spectrum of stiff person syndrome: a review of recent reports. Tremor and Other Hyperkinetic Movements 6:340. https://doi.org/10.7916/D85M65GDCrossRefPubMedPubMedCentral

54.

Pittock SJ, Lucchinetti CF, Parisi JE et al (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58:96–107. https://doi.org/10.1002/ana.20529CrossRefPubMed

55.

Tobin WO, Lennon VA, Komorowski L et al (2014) DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83:1797–803. https://doi.org/10.1212/WNL.0000000000000991CrossRefPubMedPubMedCentral

56.

Shah S, Vazquez Do Campo R, Kumar N et al (2021) Paraneoplastic myeloneuropathies: clinical, oncologic, and serologic accompaniments. Neurology 96:e632. https://doi.org/10.1212/WNL.0000000000011218CrossRefPubMedPubMedCentral

57.

Titulaer MJ, Soffietti R, Dalmau J et al (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 18:19-e3. https://doi.org/10.1111/j.1468-1331.2010.03220.xCrossRefPubMed

58.

Keime-Guibert F, Graus F, Fleury A et al (2000) Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68:479–82. https://doi.org/10.1136/jnnp.68.4.479CrossRefPubMedPubMedCentral

59.

Berzero G, Karantoni E, Dehais C et al (2018) Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry 89(7):789–792. https://doi.org/10.1136/jnnp-2017-316904CrossRefPubMed

60.

McKeon A (2016) Autoimmune encephalopathies and dementias. Contin Lifelong Learn Neurol 22(2 Dementia):538–58. https://doi.org/10.1212/CON.0000000000000299CrossRef

61.

Vernino S, O’Neill BP, Marks RS et al (2004) Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 6:55–62. https://doi.org/10.1215/S1152851703000395CrossRefPubMedPubMedCentral

62.

Bell J, Moran C, Blatt J (2008) Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 50:370–1. https://doi.org/10.1002/pbc.20899CrossRefPubMed

63.

Russo C, Cohn SL, Petruzzi MJ, De Alarcon PA (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28:284–8. https://doi.org/10.1002/(SICI)1096-911X(199704)28:4%3c284::AID-MPO7%3e3.0.CO;2-ECrossRefPubMed

64.

Mantegazza R, Meisel A, Sieb JP et al (2015) The European LEMS Registry: baseline demographics and treatment approaches. Neurol Ther 4:105–24. https://doi.org/10.1007/s40120-015-0034-0CrossRefPubMedPubMedCentral

65.

Rojas I, Graus F, Keime-Guibert F et al (2000) Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 55:713–5. https://doi.org/10.1212/WNL.55.5.713CrossRefPubMed

66.

Chinn JS, Schuffler MD (1988) Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 95:1279–86. https://doi.org/10.1016/0016-5085(88)90362-9CrossRefPubMed

67.

Kruger S, Ilmer M, Kobold S et al (2019) Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 38:268. https://doi.org/10.1186/s13046-019-1266-0CrossRefPubMedPubMedCentral

68.

Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 11:1756286418799864. https://doi.org/10.1177/1756286418799864CrossRefPubMedPubMedCentral

69.

Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659–669. https://doi.org/10.1002/ana.25708CrossRefPubMed

70.

Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https://doi.org/10.1186/s40425-019-0617-xCrossRefPubMed

71.

72.

Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9. https://doi.org/10.1136/jitc-2021-002890

73.

Chompoopong P, Zekeridou A, Shelly S et al (2022) Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J Neurol Neurosurg Psychiatry 93:112–114. https://doi.org/10.1136/JNNP-2021-326369CrossRefPubMed

74.

Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, Lopez-Chiriboga AS, Klein CJ, Mauermann M, Pittock SJ, Flanagan EPZA (2020) Neurologic autoimmunity and immune checkpoint inhibitors autoantibody profiles and outcomes. Mayo Clin. https://doi.org/10.1212/WNL.0000000000010632CrossRef

75.

Gkiozos I, Kopitopoulou A, Kalkanis A et al (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 13:1076–1082. https://doi.org/10.1016/J.JTHO.2018.04.031CrossRefPubMed

76.

Graus F (2019) Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 169(16):535–548. https://doi.org/10.1038/s41571-019-0194-4CrossRef

77.

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMRA1703481/SUPPL_FILE/NEJMRA1703481_DISCLOSURES.PDFCrossRefPubMed

78.

Fellner A, Makranz C, Lotem M et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601–609. https://doi.org/10.1007/S11060-018-2752-5CrossRefPubMed

79.

Papadopoulos KP, Romero RS, Gonzalez G, et al Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. https://doi.org/10.1634/theoncologist.2017-0344

80.

Williams TJ, Benavides DR, Patrice KA et al (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:928–933. https://doi.org/10.1001/JAMANEUROL.2016.1399CrossRefPubMed

81.

Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16(9):535–548. https://doi.org/10.1038/s41571-019-0194-4CrossRefPubMed

82.

Vogrig A, Fouret M, Joubert B et al (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol NeuroInflammation 6:e604. https://doi.org/10.1212/NXI.0000000000000604CrossRef

83.

Kawamura R, Nagata E, Mukai M et al (2017) Acute cerebellar ataxia induced by nivolumab. Intern Med 56:3357–3359. https://doi.org/10.2169/internalmedicine.8895-17CrossRefPubMedPubMedCentral

84.

Maller B, Peguero E, Tanvetyanon T (2018) Ipilimumab/nivolumab-related opsoclonus-myoclonus-ataxia syndrome variant in a patient with malignant pleural mesothelioma. J Immunother 41:411–412. https://doi.org/10.1097/CJI.0000000000000228CrossRefPubMed

85.

Matsuoka H, Kimura H, Koba H et al (2018) Nivolumab-induced limbic encephalitis with Anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597–e599. https://doi.org/10.1016/J.CLLC.2018.04.009CrossRefPubMed

86.

Kunchok A, Zekeridou A, Pittock S (2020) CRMP5-IgG–associated paraneoplastic myelopathy with PD-L1 inhibitor therapy. JAMA Neurol 77:255–256. https://doi.org/10.1001/JAMANEUROL.2019.4379CrossRefPubMed

87.

Puwanant A, Isfort M, Lacomis D, Živković SA (2019) Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord 29:127–133. https://doi.org/10.1016/J.NMD.2018.11.012CrossRefPubMed

88.

Puwanant A, Isfort M, Lacomis D, Živković SA (2019) Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord 29(2):127–133. https://doi.org/10.1016/j.nmd.2018.11.012CrossRefPubMed

89.

Agrawal K, Agrawal N (2019) Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer. https://doi.org/10.1155/2019/5353202

90.

Nakatani Y, Tanaka N, Enami T et al (2018) Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10:346. https://doi.org/10.1159/000494078CrossRefPubMedPubMedCentral

91.

Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714. https://doi.org/10.1200/JCO.2017.77.6385CrossRefPubMed

92.

Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group Equal contributors. J Immunother Cancer 5:95. https://doi.org/10.1186/s40425-017-0300-zCrossRefPubMedPubMedCentral

Title: Paraneoplastic neurological syndrome: growing spectrum and relevance
Authors: Valakunja Harikrishna Ganaraja
Mohamed Rezk
Divyanshu Dubey
Publication date: 01-06-2022
Publisher: Springer International Publishing
Keywords: SCLC
Encephalitis
SCLC
Checkpoint Inhibitors
Published in: Neurological Sciences / Issue 6/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06083-y

At a glance: The STEP trials

Springer Medicine

Paraneoplastic neurological syndrome: growing spectrum and relevance

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2022

Does erythropoietin affect the outcome and complication rates of patient with traumatic brain injury? A pooled-analysis

Stroke survivors with the same levels of exercise as healthy individuals have lower levels of physical activity

Single nucleotide variants around the connective tissue growth factor (CTGF/CCN2) gene and their association with multiple sclerosis risk, disability scores, and rate of disease progression

Negative symptoms in Huntington’s disease

Are COVID-19 vaccines safe for people with epilepsy? A cross-sectional study

Nerve ultrasound may help predicting response to immune treatment in chronic inflammatory demyelinating polyradiculoneuropathy